^
    1m
    SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Hangzhou Sumgen Biotech Co., Ltd. | Withdrawn --> Active, not recruiting | Trial completion date: Oct 2022 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Jun 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    SG301 IV
    1year
    SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
    P1, N=0, Withdrawn, Hangzhou Sumgen Biotech Co., Ltd. | N=108 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    SG301 IV
    over3years
    SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
    P1, N=108, Not yet recruiting, Hangzhou Sumgen Biotech Co., Ltd.
    Clinical • New P1 trial
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    SG301 IV